MDT Stock Analysis — Medtronic
Sector: Healthcare
AI Verdict
Medtronic trades at a steep discount to the sector on next year's earnings, and if its regulatory moat delivers the expected growth, this is cheap for the risk.
Competitive Moat
Medtronic dominates in implantable medical devices like pacemakers and insulin pumps, where FDA approvals and physician training create high switching costs. Its global scale and deep regulatory expertise make it hard for new entrants to compete in core markets.
Summary
Analysts expect Medtronic's earnings to jump 58.4% next year, driving a sharp drop in its forward P/E to 13.4x.
Where It Stands
Medtronic is down -10.29% over the past year, with an RSI of 45.3 signaling cooling sentiment, and trades at 13.4x next year's earnings versus the healthcare sector's 22x median.
Key Metrics
- RSI: 45.3 — Neutral
- Trailing P/E: 21.3x
- Forward P/E: 13.4x
- PEG Ratio: 0.37
- Earnings Growth: +0.6%
- Revenue Growth: +0.1%
- Market Cap: $101.4B
- Dividend Yield: 0.04%
- 1-Year Return: -10.29%
- 52-Week High: $106.33
- 52-Week Low: $73.31
Analyst Consensus
21 Buy · 15 Hold · 1 Sell (37 analysts)
Bull Case
You're paying just 13.4x forward earnings for a company expected to grow EPS by 58.4% next year, which is cheap for the growth on offer.
Bear Case
If the forward P/E reverts even partway back to the sector median of 22x, there's room for disappointment if that 58.4% EPS growth doesn't materialize.
Catalyst to Watch
Watch for upcoming FDA approvals or clinical trial results, as these could validate or derail the high earnings growth forecast.